# Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

> **NCT00079326** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** ixabepilone
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00079326
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2008-07
- **Final completion:** 2010-10
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2014-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079326, "Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00079326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*